Prostate cancer immunotherapy
- 1 May 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 17 (3), 175-181
- https://doi.org/10.1097/mou.0b013e3280eb10eb
Abstract
Basic immunology research over several decades has led to an improved understanding of tumor recognition by components of the immune system and mechanisms of tumor evasion from immune detection. These findings have ultimately led to four phase III trials, currently underway, evaluating antitumor active immunotherapies in patients with prostate cancer. This article reviews recent published findings in the area of prostate cancer immunotherapies, focusing on both passive and active immunotherapy approaches that have entered clinical trials. Clinical trials with immune active agents reported in the last year have demonstrated efficacy in the treatment of prostate cancer. These agents include immune modulators such as granulocyte-macrophage colony stimulating factor and anticytotoxic T-lymphocyte-associated antigen 4 monoclonal antibodies, antibody therapies targeting prostate-specific membrane antigen, and vaccines such as those targeting prostatic acid phosphatase, prostate-specific antigen, and cellular vaccines expressing granulocyte-macrophage colony stimulating factor. Results from several recent clinical trials have suggested that immune-based therapies have clinical benefit in patients with prostate cancer with potentially less toxicity than traditional systemic treatments. We review recent reports of immunotherapies being evaluated in patients with prostate cancer, and highlight the direction for these therapies in combination with other immunotherapies and other traditional therapies.Keywords
This publication has 55 references indexed in Scilit:
- Do Patients With Localized Prostate Cancer Treatment Really Want More Aggressive Treatment?Journal of Clinical Oncology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancerUrologic Oncology: Seminars and Original Investigations, 2005
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate CancerJournal of Clinical Oncology, 2003
- Phase II Trial of GM-CSF in Advanced Prostate CancerInvestigational New Drugs, 2001
- Cytokine regulation of eosinophil functionClinical Immunology and Immunopathology, 1992
- Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.Journal of Clinical Investigation, 1990
- Human granulocyte-macrophage colony-stimulating factor is a neutrophil activatorNature, 1985